Acute methylenedioxymethamphetamine administration: Effects on local cerebral blood flow and glucose utilisation in the dark agouti rat

Psychopharmacology

Volumn 173, Issue 3-4, 2004, Pages 287-295

  Quate, Linda ^a   McBean, Douglas E ^a   Ritchie, Isobel M ^b   Olverman, Henry J ^b   Kelly, Paul A T ^b  

^a QUEEN MARGARET UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

5 Hydroxytryptamine; Cerebrovascular accident; Ecstasy; Flow metabolism coupling; Oligaemia

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; CARBON 14; DEOXYGLUCOSE; GLUCOSE; IODOPHENAZONE C 14; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN BLOOD FLOW; BRAIN METABOLISM; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; GLOBUS PALLIDUS; GLUCOSE BRAIN LEVEL; GLUCOSE UTILIZATION; MALE; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; RAT; RAT STRAIN; SUPERIOR COLLICULUS; THALAMUS ANTERIOR NUCLEUS;

ANIMALS; BRAIN; CEREBROVASCULAR CIRCULATION; GLUCOSE; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS;

EID: 2542544234     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-1784-z     Document Type: Article

References (49)

1. Auer J, Berent R, Weber T, Lassnig E, Eber B (2002) Subarachnoid haemorrhage with "Ecstasy" abuse in a young adult. Neurol Sci 23:199-201
2. Battaglia G, Yeh SY, De Souza EB (1988) MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol Biochem Behav 29:269-274
3. Colado MI, Williams JL, Green AR (1995) The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol 115:1281-1289
4. Cole J, Sumnall HR, Grob CS (2002) Sorted: ecstasy. Psychologist 15:464-467
5. Edvinsson L, MacKenzie ET (1977) Amine mechanisms in the cerebral circulation. Pharmacol Rev 28:275-348
6. Edvinsson L, Degueurce A, Duverger D, MacKenzie ET, Scatton B (1983) Central serotonergic nerves project to the pial vessels of the brain. Nature 306:55-57
7. Edvinsson L, McCulloch J, Sharkey J (1985) Vasomotor responses of cerebral arterioles in situ to putative dopaminergic receptor agonists. Br J Pharmacol 85:403-410
8. Frederick DL, Paule MG (1997) Effect of MDMA on complex brain function in laboratory animals. Neurosci Biobehav Rev 21:67-78
9. Green AR, Cross AJ, Goodwin GM (1995) Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy'). Psychopharmacology 119:247-260
10. Hanyu S, Ikeguchi K, Imai H, Imai N, Yoshida M (1995) Cerebral infarction associated with 3,4-methylenedioxymethamphetamine ('ecstasy') abuse. Eur Neurol 35:173
11. Harries DP, De Silva R (1992) 'Ecstasy' and intracerebral haemorrhage. Scott Med J 37:150-152
12. Kaku DA, Lowenstein DH (1990) Emergence of recreational drug abuse as a major risk factor for stroke in young adults. Ann Intern Med 113:821-827
13. Kelly PAT, McCulloch J (1984) Extrastriatal circuits activated by intrastriatal muscimol: a 14C-2-deoxy glucose investigation. Brain Res 292:357-366
14. Kelly PAT, Graham DI, Mcculloch J (1982) Specific alterations in local cerebral glucose utilization following striatal lesions. Brain Res 233:157-172
15. Kelly PAT, Ritchie IM, Collins FM (1995) Cerebrovascular consequences of repeated exposure to NG-nitro-L-arginine. Br J Pharmacol 116:2771-2777
16. Koch S, Galloway MP (1997) MDMA induced dopamine release in vivo: role of endogenous serotonin. J Neural Transm 104:135-146
17. Kokotos Leonardi ET, Azmitia EC (1994) MDMA (Ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology 10:231-238
18. Kuschinsky W, Wahl M (1978) Local chemical and neurogenic regulation of cerebrovascular resistance. Physiol Rev 58:656-689
19. Li AA, Marek GJ, Vocmer G, Seiden LS (1989) Long-term central 5-HT depletions resulting from repeated administration of MDMA enhances the effects of single administration of schedule-controlled behaviour of rats. Pharmacol Biochem Behav 33:641-648
20. Lou HC, Edvinsson L, MacKenzie ET (1987) The concept of coupling blood flow to brain function: revision required? Ann Neurol 22:289-297
21. Malpass A, White JM, Irvine RJ, Somogyi AA, Bochner F (1999) Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and Dark Agouti rats. Pharmacol Biochem Behav 64:29-34
22. McBean DE, Sharkey J, Ritchie IM, Kelly PAT (1990) Evidence for a possible role for serotonergic systems in the control of cerebral blood flow. Brain Res 537:307-310
23. McBean DE, Sharkey J, Ritchie IM, Kelly PAT (1991) Cerebrovascular and functional consequences of 5-HT1A receptor activation. Brain Res 555:159-163
24. McBean DE, Ritchie IM, Olverman HJ, Kelly PAT (1999) Effects of the specific serotonin reuptake inhibitor, citalopram, upon local cerebral blood flow and glucose utilisation in the rat. Brain Res 847:80-84
25. McCulloch J, Kelly PAT, Ford I (1982) The effect of apomorphine on the relationship between local cerebral glucose utilization and local cerebral blood flow with an appendix on its statistical analysis. J Cereb Blood Flow Metab 2:487-499
26. McEvoy AE, Kitchen ND, Thomas DGT (2000) Intracerebral haemorrhage in young adults: the emerging importance of drug misuse. BMJ 320:1322-1324
27. McKenna DJ, Peroutka SJ (1990) Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"). J Neurochem 54:14-22
28. Miranda J, O'Neill D (2002) Stroke associated with amphetamine use. Ir Med J 95:281-282
29. Nichols DE (1986) Differences between the mechanism of action of MDMA, MBDB and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 18:305-313
30. Nichols DE, Oberlender R (1990) Structure-activity relationships of MDMA and related compounds: a new class of psychoactive drugs? Ann N Y Acad Sci 600:612-623
31. O'Loinsigh ED, Boland G, Kelly JP, O'Boyle KM (2001) Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the Wistar rat. Prog Neuropsychopharmacol Biol Psychiatry 25:621-638
32. O'Shea E, Granados R, Esteban B, Colado MI, Green AR (1998) The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology 37:919-926
33. Parrot AC (2001) Human psychopharmacology of ecstasy (MDMA): a review of 15 years of empirical research. Hum Psychopharmacol 16:557-577
34. Perez JA, Arsura EL, Strategos S (1999) Methamphetamine-related stroke: four cases. J Emerg Med 17:469-471
35. Petitti DB, Sidney S, Queensberry C, Bernstein A (1998) Stroke and cocaine or amphetamine use. Epidemiology 9:596-600
36. Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32-41
37. Rudnick G, Wall SC (1992) The molecular mechanism of "ecstasy" [3,4-methylenedioxymethamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci U S A 89:1817-1821
38. 14C]antipyrine. Am J Physiol 234:H59-H66
39. Scanzello CR, Hatzidimitriou G, Martello AL, Katz JL, Ricaurte GA (1993) Serotonergic recovery after (±)3,4-(methylenedioxy)methamphetamine injury: observations in rats. J Pharmacol Exp Ther 264:1484-1491
40. Schmidt CJ (1987) Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J Pharmacol Exp Ther 240: 1-7
41. Schmidt CJ (1989) Acute and long-term neurochemical effects of methylenedioxymethamphetamine in the rat. NIDA Res Monogr 94:179-195
42. Schmidt CJ, Wu L, Lovenberg W (1986) Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue. Eur J Pharmacol 124:175-178
43. 14C]deoxyglucose method for the measurement of local cerebral glucose utilisation: theory, procedure and normal values in the conscious and anesthetized albino rat. J Neurochem 28:897-916
44. Stone DM, Stahl DC, Hanson GR, Gibb JW (1986) The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain. Eur J Pharmacol 128:41-48
45. Stone DM, Merchant KM, Hanson GR, Gibb JW (1987) Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 26:1677-1683
46. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, Hiratsuka A, Schmitz DA, Chu TYY (1994) The demethylenation of methylenedioxymethamphetamine ("Ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 47:1151-1156
47. White SR, Obradovic T, Imel KM, Wheaton MJ (1996) The effects of methylenedioxymethamphetamine (MDMA, 'Ecstasy') on monoaminergic neurotransmission in the central nervous system. Prog Neurobiol 49:455-479
48. Wichems CH, Hollingsworth CK, Bennett BA (1995) Release of serotonin induced by 3,4-methylenedioxymethamphetamine (MDMA) and other substituted amphetamines in cultured fetal raphe neurons: further evidence for calcium-independent mechanisms of release. Brain Res 695:10-18
49. Wilkerson G, London ED (1989) Effects of methylenedioxymethamphetamine on local cerebral glucose utilization in the rat. Neuropharmacology 28:1129-1138